Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ICER Determines OCA’s Benefit In NASH Might Support Limited Approval

Jul 22 2020

• By Joseph Haas

Businessman balancing between cost and benefit in business conce — ICER says OCA's risk-benefit ratio might only support use in sicker patients

Related Content

Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate

Nov 17 2014

Intercept CRL Likely About OCA-Specific Concerns, Not NASH Endpoints

Jun 30 2020

Intercept’s CRL Just Continues Upheaval In NASH

Jun 29 2020

RESOLVE-IT Failure Dashes Genfit's NASH Hopes

May 12 2020

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

Jul 10 2019

Intercept Retakes The Lead In NASH

Feb 19 2019

Intercept’s Early NASH Efforts Will Stress Advanced Fibrosis

Dec 17 2019

Ocaliva In NASH Manageable With Indication-Based Pricing, ICER Roundtable Suggests

Jul 29 2016

Related Companies

Intercept Pharmaceuticals, Inc.

Genfit SA

Additional Topics

Cost Effectiveness Drug Safety Drug Approval Standards Commercial Liver & Hepatic BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window